today announc approv tazverik es w/ clean label w/o black box warn
put bed prior secondari malign concern es small prime market
ahead fl approv price line w/ est initi launch
modest acceler w/ fl approv model fl sale approv
new pt base previous ep discount
rais pt anticip price-to-earnings multipl expand given es approv
clean label higher likelihood broad fl approv fl
comprehens royalti pharma deal remov financ overhang sever
year reduc discount rate reflect lower risk face
asset use year profit feel alway good
baromet futur ep growth sustain profit typic employ
price-to-earnings multipl year growth stock often trade multipl
year
recal sold common stock
sold addit common stock royalti pharma
ye cash support runway
launch drug within busi day es ini- patient
 qualifi label estim predict market share rise
view possibl patient commenc therapi faster
would prefer err conserv side
note es sever soft tissu diseas high unmet need estim
patient live es patient us
diagnos elig tazverik patient metastat diseas short overal
surviv os medium os year
estim soft tissu sarcoma patient care sever center
excel genet screen alway perform patient compani
note es often under-diagnos therefor launch campaign
promot awar es help physician properli diagnos es patient
initi phase confirmatori studi es dec global random
confirmatori studi primarili eu test tazverik doxorubicin vs placebo
doxorubicin cycl follow tazverik vs placebo mainten phase diseas
progress initi safeti run-in phase escal dose taze
doxo test choos optim dose combin efficaci phase
pleas see page report import disclosur
classic turnaround emerg hardship tazverik de-risk asset
fda approv epithelioid sarcoma es consult enthusiast
anticip peak sale make attract overlook opportun tazverik
file dec follicular lymphoma fl high convict tazverik
approv fl mut data bigger wt less robust
still approv given drug meaning efficaci clean safeti profil concern
partial clinic hold due secondari malign patient overdon
address label believ stock offer attract profil given
upsid potenti late stage asset
fda decis fl us
complet safeti evalu tazverik
r/r fl
initi studi tazverik parpi
platinum-resist solid tumor
tazverik reach peak sale
tazverik approv
epitheloid sarcoma fl
wt
tazverik safeti
issu sinc one case malign
transform led prior
tazverik sale reach move
fl
get acquir attract
tazverik approv wt fl
need addit capit
focus epigenet develop small molecul inhibitor
histon methyltransferas hmt play key role regul gene
express tazverik tazemetostat oral small molecul inhibitor well-
character hmt ph ii trial relapsed/refractori nhl ph ii adult ph
pediatr genet defin refractori solid tumor tazverik file fda approv
follicular lymphoma approv epithelioid sarcoma es jan
anticip regulatori decis fl
safeti run-in began dec efficaci studi expect commenc
primari endpoint secondari endpoint includ os orr dor
primari complet expect sept accord ct gov note studi
expect take year complet
es small indic model peak sale peak penetr es
es approv posit readthrough nda review fl
submit dec recal success pre-nda meet fda oct
fl file phase data support fl fill present dec
view es opportun small bode well far greater commerci
opportun fl
recal submit es fill review divis oncolog product
fl fill made divis hematolog product dhp
team review clinic modul common technic modul
includ preclin data review team within oncolog
divis henc es review expect streamlin review process fl
es launch prime market fl upon anticip approv
initi phase studi test tazverik revlimid plu rituxan vs
placebo fl jan primari endpoint also plan
commenc futur studi includ tazverik rituxan fl r-chop high
like robust pipelin provid posit upsid label expans
cowen compani
epizym quarterli us eu incom incom loss incom tax incom ep option net tax incom ex non-cash stock option ep outstand cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
forecast sale product difficult outlook could alter
competit clinic develop failur reimburs chang new competit
could also impact sale estim pipelin product might fail develop
risk includ clinic develop regulatori price commerci challeng may
prevent financi forecast materi
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock argenx secur
cowen compani llc manag co-manag public offer argenx past month
cowen compani llc receiv compens invest bank servic argenx past month
argenx past month client cowen compani llc cowen compani llc provid provid invest bank servic
past month
cowen compani llc and/or affili expect receiv intend seek compens invest bank servic next month argenx
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
